OBJECTIVE: To better understand the seemingly contradictory plasma beta-amyloid (Abeta) results in Alzheimer's disease (AD) patients by using a newly developed plasma Abeta assay, the INNO-BIA plasma Abeta forms, in a multicenter study. METHODS: A combined retrospective analysis of plasma Abeta isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers. RESULTS: Detection modules based on two different amino (N)-terminal specific Abeta monoclonal antibodies demonstrated that Abeta in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low Abeta42 plasma concentrations. Abeta40 and Abeta42 concentrations varied consistently with the ApoE genotype, while the Abeta42/Abeta40 ratio did not. Irrespective of the decrease of the Abeta42/Abeta40 ratio with age and MMSE, this parameter was strongly associated with AD, as defined in this study by elevated hyperphosphorylated (P-tau181P) levels in cerebrospinal fluid (CSF). CONCLUSION: A highly robust assay for repeatedly measuring Abeta forms in plasma such as INNO-BIA plasma Abeta forms might be a useful tool in a future risk assessment of AD.
OBJECTIVE: To better understand the seemingly contradictory plasma beta-amyloid (Abeta) results in Alzheimer's disease (AD) patients by using a newly developed plasma Abeta assay, the INNO-BIA plasma Abeta forms, in a multicenter study. METHODS: A combined retrospective analysis of plasma Abeta isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers. RESULTS: Detection modules based on two different amino (N)-terminal specific Abeta monoclonal antibodies demonstrated that Abeta in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low Abeta42 plasma concentrations. Abeta40 and Abeta42 concentrations varied consistently with the ApoE genotype, while the Abeta42/Abeta40 ratio did not. Irrespective of the decrease of the Abeta42/Abeta40 ratio with age and MMSE, this parameter was strongly associated with AD, as defined in this study by elevated hyperphosphorylated (P-tau181P) levels in cerebrospinal fluid (CSF). CONCLUSION: A highly robust assay for repeatedly measuring Abeta forms in plasma such as INNO-BIA plasma Abeta forms might be a useful tool in a future risk assessment of AD.
Authors: F H Bouwman; S N M Schoonenboom; W M van der Flier; E J van Elk; A Kok; F Barkhof; M A Blankenstein; Ph Scheltens Journal: Neurobiol Aging Date: 2006-06-19 Impact factor: 4.673
Authors: Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen Journal: JAMA Date: 2003 Apr 23-30 Impact factor: 56.272
Authors: N Ertekin-Taner; L H Younkin; D M Yager; F Parfitt; M C Baker; S Asthana; M L Hutton; S G Younkin; N R Graff-Radford Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: Oskar Hansson; Henrik Zetterberg; Eugeen Vanmechelen; Hugo Vanderstichele; Ulf Andreasson; Elisabet Londos; Anders Wallin; Lennart Minthon; Kaj Blennow Journal: Neurobiol Aging Date: 2008-05-19 Impact factor: 4.673
Authors: F H Bouwman; W M van der Flier; N S M Schoonenboom; E J van Elk; A Kok; F Rijmen; M A Blankenstein; P Scheltens Journal: Neurology Date: 2007-09-04 Impact factor: 9.910
Authors: Henrik Zetterberg; Mona Pedersen; Karin Lind; Maria Svensson; Sindre Rolstad; Carl Eckerström; Steinar Syversen; Ulla-Britt Mattsson; Christina Ysander; Niklas Mattsson; Arto Nordlund; Hugo Vanderstichele; Eugeen Vanmechelen; Michael Jonsson; Ake Edman; Kaj Blennow; Anders Wallin Journal: J Alzheimers Dis Date: 2007-11 Impact factor: 4.472
Authors: Piotr Lewczuk; Hermann Esselmann; Mirko Bibl; Georg Beck; Juan Manuel Maler; Markus Otto; Johannes Kornhuber; Jens Wiltfang Journal: J Mol Neurosci Date: 2004 Impact factor: 2.866
Authors: Husam Ghanim; Scott V Monte; Chang Ling Sia; Sanaa Abuaysheh; Kelly Green; Joseph A Caruana; Paresh Dandona Journal: J Clin Endocrinol Metab Date: 2012-04-16 Impact factor: 5.958
Authors: Jon B Toledo; Hugo Vanderstichele; Michal Figurski; Paul S Aisen; Ronald C Petersen; Michael W Weiner; Clifford R Jack; William Jagust; Charles Decarli; Arthur W Toga; Estefanía Toledo; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Leslie M Shaw Journal: Acta Neuropathol Date: 2011-07-30 Impact factor: 17.088
Authors: Sid E O'Bryant; Michelle M Mielke; Robert A Rissman; Simone Lista; Hugo Vanderstichele; Henrik Zetterberg; Piotr Lewczuk; Holly Posner; James Hall; Leigh Johnson; Yiu-Lian Fong; Johan Luthman; Andreas Jeromin; Richard Batrla-Utermann; Alcibiades Villarreal; Gabrielle Britton; Peter J Snyder; Kim Henriksen; Paula Grammas; Veer Gupta; Ralph Martins; Harald Hampel Journal: Alzheimers Dement Date: 2016-11-18 Impact factor: 21.566
Authors: Maria Bjerke; Erik Portelius; Lennart Minthon; Anders Wallin; Henrik Anckarsäter; Rolf Anckarsäter; Niels Andreasen; Henrik Zetterberg; Ulf Andreasson; Kaj Blennow Journal: Int J Alzheimers Dis Date: 2010-07-15
Authors: Anne M Fagan; Mark A Mintun; Aarti R Shah; Patricia Aldea; Catherine M Roe; Robert H Mach; Daniel Marcus; John C Morris; David M Holtzman Journal: EMBO Mol Med Date: 2009-11 Impact factor: 12.137